Xponance Inc. buys new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Xponance Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) during the second quarter, Holdings Channel.com reports. The institutional investor bought 10,214 shares of the company’s stock, valued at approximately $65,000.

A number of other hedge funds and other institutional investors have added to or reduced their stakes in the company. Profund Advisors LLC raised its position in Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after buying an additional 1,680 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Amneal Pharmaceuticals by 8.6% in the first quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock worth $133,000 after buying an additional 1,726 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Amneal Pharmaceuticals by 18.8% in the first quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock worth $122,000 after buying an additional 3,177 shares in the last quarter. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals in the second quarter valued at about $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Amneal Pharmaceuticals by 13.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after acquiring an additional 4,115 shares in the last quarter. 31.82% of shares are held by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $8.55 on Friday. The firm has a market cap of $2.64 billion, a PE ratio of -15.27 and a beta of 1.18. The company has a quick ratio of 0.82, a current ratio of 1.33, and a debt-to-equity ratio of 121.31. The company has a 50-day moving average of $8.14 and a 200-day moving average of $7.05. Amneal Pharmaceuticals, Inc. has a 12-month low of $3.36 and a 12-month high of $8.94.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Your Free Report ) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The company had revenue of $701.78 million for the quarter, compared to the consensus estimate of $657.43 million. As a group, sell-side analysts expect Amneal Pharmaceuticals, Inc. to post 0.52 earnings per share for the current year.

Analyst upgrades and downgrades

AMRX has been the subject of a number of recent research reports. Barclays boosted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $9.40, based on data from MarketBeat.

Check out the latest stock report on AMRX

About Amneal Pharmaceuticals

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets and distributes generic, injectable, biosimilar and specialty brand pharmaceutical products worldwide. The company operates through three segments: Generic, Specialty and AvKARE. The Generics segment offers oral solid, powder, liquid, sterile injectable, nasal spray, inhaler and respiratory, biosimilar, ophthalmic, film, transdermal patch and topical immediate and extended release products.

Featured stories

Want to see what other hedge funds own AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report).

Get daily news and reviews for Amneal Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.